Chemical tools to map inflammatory protein networks in cancer and other diseases
Official title: Chemical proteomics strategies for quantifying inflammatory protein networks and modifications
Funded at University of Texas Arlington · NIH-11396274 · Data updated 2026-11-12
A patient-friendly project that uses advanced chemistry and mass spectrometry to understand how inflammatory proteins interact in diseases like cancer, with the goal of uncovering new ways to treat or better manage these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Arlington NIH-funded |
| Lab location | 1 site (Arlington, United States) |
| Project start | September 1, 2025 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $373,397 |
| NIH project number | 5R35GM158399-02 |
| Project ID | NIH-11396274 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with inflammatory conditions or cancer where PRR signaling is involved could benefit from future translational approaches influenced by this research.
✕Less likely to help
Direct clinical benefits may not be immediate; findings may take years to translate into therapies for some conditions.
What this research studies
This project will study how inflammatory signaling proteins are activated and interact with each other in human disease using innovative chemical proteomics. Researchers will map networks and modifications of key receptors such as TLRs and NLRs to reveal how signals drive disease processes. The work involves cutting-edge mass spectrometry and targeted biochemical methods to quantify protein interactions and modifications in complex samples. Findings could point to new biomarkers or targets for therapies in cancers and inflammatory diseases. Participation would advance our understanding of disease biology and could inform future patient-directed research sooner rather than later.
Why it matters
Potential benefit: Could lead to new targets or biomarkers that improve cancer and inflammatory disease diagnosis and treatment.
How similar studies have gone: Similar proteomics approaches have successfully mapped signaling networks in other diseases, supporting the potential for meaningful insights here.
Where this research is happening
-
University of Texas Arlington
Arlington, United States Active
Researchers
- Principal investigator: Chowdhury, Saiful M — University of Texas Arlington
- Study coordinator: Chowdhury, Saiful M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.